Event Videos

http://www.ncbi.nlm.nih.gov/pubmed/23811112

Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E,Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I,Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Randomized controlled trial of danoprevir plus peginterferonalfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype1 infection. Gastroenterology.

Published on: 
Oct-2013

http://www.ncbi.nlm.nih.gov/pubmed/24010644

 

Lawitz EJ, Rodriguez-Torres M, Denning J, Mathias A, Mo H, Gao B, Cornpropst MT, Berrey MM, Symonds WT. All-oral therapy with nucleotide inhibitors sofosbuvirand GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). JViral Hepat. 2013 Oct; 20(10):699-707.

 

Abstract

 

Published on: 
Oct-2013

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: